Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $431.82M. Across the group, the median move over the past trading day is −0.73%. Price change over the past year runs from −30.9% to +23.3% across the middle 80 percent of the group, with a median of −25.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| ABVX.PA | ABIVAX Société Anonyme | $10.42B | Large cap | +42.59% | Sep 21, 2026 |
| RZLT | Rezolute, Inc. | $482.42M | Small cap | −28.43% | Sep 16, 2026 |
| CUV.AX | Clinuvel Pharmaceuticals Limited | $381.21M | Small cap | −21.84% | Aug 27, 2026 |
| 0AB6.L | Hyloris Pharmaceuticals SA | $185.32M | Small cap | −32.01% | Sep 24, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.